Amcure Gmbh

amcure, a spin-off from the Karlsruhe Institute of Technology, develops a first-in-class approach for the treatment of metastatic cancers. Our allosteric inhibitors are unique in that they show significant efficacy in relevant POC animal studies against highly metastatic epithelial cancers. Our peptide-based compounds target the tumor specific co-receptor CD44v6. Complex formation with CD44v6 is a prerequisite for the activation of several receptor tyrosine kinases (RTKs) that are instrumental for angiogenesis and metastasis (e.g. VEGFR-2 and c-Met). The mode of action of our approach differs fundamentally from known experimental or approved compounds in this area, which in most cases either address only a single RTK or target multiple RTKs as broadband inhibitors. By targeting CD44v6 our compounds combine the advantages of receptor specificity and broadband inhibition.